Compare Quest Diagnostics Inc (DGX) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NetApp Inc. — how do they compare? Quest Diagnostics Inc trades at $230.2 (market cap $25.48B), while NetApp Inc. trades at $232.79 (market cap $45.38B). The key difference: NetApp Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and NetApp Inc. for 57 Days on average.
| DGX | NTAP | |
|---|---|---|
Market Cap | $25.48B | $45.38B |
Volume | 941,866 | 2,264,311 |
Sector | Health | Technology |
52-Week High | $247.45 | $235.84 |
52-Week Low | $173.49 | $94.11 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $31.23B | $44.34B |
Dividend Yield | 1.49% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
NetApp (NTAP) trades at $235.84, up 3.23% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Fundamentally, the company maintains robust profitability with 70.63% gross margins and 19.19% net income margin. Recent AI infrastructure partnerships with Oracle, SAP, and Supermicro position NTAP for growth in the expanding AI data storage market.
Outlook remains positive with AI-driven demand creating new revenue opportunities, though valuation multiples appear elevated. Key risks include competitive pressures in cloud storage and potential market volatility. Analyst consensus leans neutral with 50.7% hold ratings, suggesting cautious optimism amid strong technical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
